Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
GM partners with LG to launch a new US-made 400-mile EV battery in 2028, aiming to achieve price parity between electric and gasoline vehicles.
Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
GM partners with LG to launch a new US-made 400-mile EV battery in 2028, aiming to achieve price parity between electric and gasoline vehicles.